ArticleFrontiers in oncology2025
Downregulation of SALL1 and its association with poor prognosis and the immune cell landscape in clear cell renal cell carcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Spalt-like transcription factor 1 (SALL1), a member of the Krüppel-associated box-containing zinc finger proteins, has been implicated in tumor suppression, epigenetic regulation, and immune modulation in several malignancies. However, its role in clear cell renal cell carcinoma (ccRCC) remains poorly understood. This study aims to comprehensively assess the clinical significance, immunological relevance, and potential therapeutic value of SALL1 in ccRCC. Methods: We analyzed transcriptomic and clinical data from public databases to explore the expression, prognostic value, and clinical correlations of SALL1 in ccRCC. The immune cell landscape associated with SALL1 was assessed using various immune algorithms. SALL1 expression in ccRCC tissues and cells was validated by immunohistochemistry (IHC), RT-qPCR, and Western blot analyses. Gene Ontology and KEGG pathway analyses were employed to identify the potential biological functions of SALL1. Functional assays, including MTT, colony formation, and Transwell assays, were performed to evaluate the effects of SALL1 on ccRCC cell proliferation, invasion, and migration. Results: SALL1 expression was significantly downregulated in ccRCC tumors compared to normal tissues. Overexpression of SALL1 inhibited cell proliferation, migration, and invasion in A498 and 769-P cell lines. Survival analysis revealed that low SALL1 expression was associated with poor overall survival, progression-free survival, and disease-specific survival. Univariate and multivariate Cox regression analyses confirmed that SALL1 expression is an independent prognostic factor for ccRCC. Functional enrichment analyses indicated that genes associated with SALL1 were enriched in pathways related to ion transport and immune modulation. Furthermore, SALL1 also exhibited positive correlations with the sensitivity to multiple anticancer agents. Conclusions: SALL1 is significantly downregulated in ccRCC and independently predicts poor clinical outcomes. It exerts tumor-suppressive effects and is involved in shaping an immunologically favorable tumor microenvironment. Functional assays confirmed its ability to enhance drug responsiveness, especially to Sunitinib. These findings suggest that SALL1 may serve as a prognostic biomarker and a potential modulator of immune and therapeutic responses in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.